Meta-Analysis: Greater Control at Baseline A1C Levels with Liraglutide Compared to Other Therapies

Data presented today at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) showed that regardless of baseline A1C, once-daily Victoza® (liraglutide [rDNA origin] injection, Novo Nordisk) 1.8 mg consistently helped more patients achieve blood sugar control than some other commonly used T2DM (type 2 diabetes) therapies. Victoza® is the first and only human glucagon-like peptide-1 (GLP-1) analog that is 97% similar to endogenous human GLP-1.

The study is a meta-analysis (combined results from several studies) of seven studies on Victoza® (liraglutide [rDNA origin] injection), including the six phase III LEAD (Liraglutide Effect and Action in Diabetes) studies, performed to determine the mean changes in A1C from baseline to week 26. Victoza® (liraglutide [rDNA origin] injection) 1.8 mg was compared with exenatide, insulin glargine, glimepiride, rosiglitazone, and sitagliptin. Baseline A1C categories included less than or equal to 7.5%, >7.5-8.0%, >8.0-8.5%, >8.5-9.0%, >9.0%. Logistic regression was also used to compare the percentage of patients achieving the AACE target A1C of less than or equal to 6.5%.

The study determined that all diabetes therapies improved blood sugar control across all baseline A1C categories, with greater reductions at higher baseline A1C levels as compared to placebo (added to background therapy). The greatest reductions were observed in the Victoza® group and ranged from 0.7% in the less than or equal to 7.5% category to 1.8% in the >9.0% category.

Victoza® reductions were followed by insulin glargine (0.3-1.5%) and exenatide (0.4-1.3%). Patients taking sitagliptin experienced no reduction in the less than or equal to 7.5% category to 1.1% in the >9.0% category. Patients taking sulfonylureas had a 0.4%-1.4% reduction. Patients treated with thiazolidinediones (TZDs) had the narrowest margin of reduction, from 0.4% in the less than or equal to 7.5% category to 0.8% in the >9.0% category.

"What is so encouraging about these data is that Victoza®, at all baseline A1C levels, helped type 2 diabetes patients achieve improved blood sugar control," said Dr. Robert Henry, President, Medicine & Science of the American Diabetes Association and Professor of Medicine, Department of Medicine, Division of Endocrinology and Metabolism at the University of California, San Diego. "This is particularly promising since we know many type 2 diabetes patients continue to struggle with blood sugar control."

Key findings
- Overall A1C reductions achieved with Victoza® were greater than reductions observed with comparator therapies across all baseline A1C categories.
- The number of patients achieving the AACE target A1C of less than or equal to 6.5% demonstrates the benefit of Victoza® across all baseline A1C categories.
- A greater proportion of patients achieved the AACE A1C target with Victoza® than with comparator therapies in the lower range of baseline A1C categories.
Significantly more patients (63%) in the baseline less than or equal to 7.5% category, treated with Victoza®, achieved the AACE recommended A1C target of less than or equal to 6.5% as compared to other anti-diabetic therapies (20-49%).

Views: 139

Tags: A1C, AACE, Endocrinologists, Novo-Nordisk, T2DM, Victoza, diabetes, liraglutide, meta-analysis, origin, More…rDNA


You need to be a member of The Diabetes Challenge to add comments!

Join The Diabetes Challenge


About Diabetes Mellitus

Diabetes Mellitus (DM) is a common metabolic disorder associated with abnormally high blood sugar levels. Diabetes is classified as either type 1 (T1DM), which is characterized by severely diminished insulin production, or type 2 (T2DM), which is characterized by moderately diminished insulin production in conjunction with insulin resistance (insensitivity of the tissues of the body to insulin). Insulin is a hormone that regulates blood glucose levels. Diabetes can seriously impair overall quality of life and may lead to multiple complications including heart disease, stroke, and kidney failure. According to the International Diabetes Federation, more than 245 million people have diabetes, with type 2 diabetes being the most prevalent.

The Diabetes Challenge is now on Twitter! Join us today so you can stay up to date with our most current blog articles! Click here to follow us!